. This study presents in vitro susceptibility data on aerobic and facultatively anaerobic bacteria tested with N-formimnidoyl thienamycin and other antibiotics in current use in the treatment of infections with common pathogens. In contrast to investigations done in academic and university institutions, which may utilize relatively resistant organisms, isolates for the present study were collected sequentially from clinical infections encountered in a large community hospital. 
this drug was the most active agent tested against 162 gram-negative bacilli. It inhibited more than 95% of the gram-negative isolates at a concentration of c2 ,ig/ml. N-Formimidoyl thienamycin was as active or more active than tobramycin against Escherichia coli, Pseudomonas aeruginosa, and Proteus mirabilis and substantially more active than ticarcillin. All 16 isolates of Klebsiellapneumoniae were inhibited by c0.5 jLg of N-formimidoyl thienamycin per ml. The marked in vitro activity of this drug against a wide variety of clinical isolates makes it a promising new antibiotic.
MK0787 (N-formimidoyl thienamycin) is a
crystalline derivative of the new ,B-lactam antibiotic thienamycin. Thienamycin exhibits potent activity against a wide variety of aerobic and anaerobic bacteria (5, 6) . However, thienamycin also possesses considerable chemical instability, remaining active only within a relatively narrow range of pH, temperature, and antibiotic concentration (2) . N-Formimidoyl thienamycin has greater stability in both the solid state and solution (K. J. Wildonger, W. J. Leanza, T. W. Miller, and B. G. Christensen, Program Abstr. Intersci. Conf. Antimicrob. Agents Chemother. 19th, Boston, Mass., abstr. no. 232, 1979) .
This study presents in vitro susceptibility data on aerobic and facultatively anaerobic bacteria tested with N-formimnidoyl thienamycin and other antibiotics in current use in the treatment of infections with common pathogens. In contrast to investigations done in academic and university institutions, which may utilize relatively resistant organisms, isolates for the present study were collected sequentially from clinical infections encountered in a large community hospital. Determination of ,8-lactamase activity. ,B-Lactamase activities of staphylococcal isolates were tested with the chromogenic cephalosporin nitrocefate (compound 87/312) (Glaxo Research Ltd., Greenford, England), using the method described by Montgomery et al. (4) .
MATERIALS AND METHODS

Microorganisms
RESULTS
The comparative in vitro activities of N-formimidoyl thienamycin, penicillin G, ampicillin, cephalothin, tobramycin, and ticarcillin are shown in Table 1. N-Formimnidoyl thienamycin appeared to be the most active agent against S. aureus, Staphylococcus epidermidis, and enterococci. More than 90% of all staphylococci were inhibited by N-formimidoyl thienamycin at a concentration of 0.125 ,ug/ml. Fourfold-greater concentrations of cephalothin were required to inhibit 90% of the S. aureus isolates; against S. epidermidis, eightfold-greater concentrations were required (Fig. 1) .
N-Formimidoyl thienamycin inhibited both ,8-lactamase-producing and non-f8-lactamaseproducing staphylococcal isolates. All 51 f8-lactamase-producing isolates of S. aureus and 6 of 7 (86%) ,3-lactamase-producing isolates of S. epidermidis were inhibited by 0.125 ,ug of N-forniimidoyl thienamycin per ml. Only 2 of 45 enterococci were not inhibited by 1 Ag of N-formimidoyl thienamycin per ml. Only one isolate was inhibited by that concentration of ampicillin (Fig. 2) . All nine isolates of group B streptococci were inhibited by the lowest concentrations of N-formimidoyl thienamycin, cephalothin, and penicillin G tested. The-activity of N-formimidoyl thienamycin against gram-negative bacilli compared favorably with the activities of tobramycin and ticarcillin. N-Formimidoyl thienamycin inhibited more than 95% of the 162 gram-negative isolates when tested at a concentration of 2 ,ug/ml. At this same concentration, ticarcillin and tobramycin inhibited 25 and 80% of the isolates, respectively. As Fig. 3 shows, N-formimidoyl thienamycin was as active or more active than tobramycin against E. coli and P. aeruginosa and substantially more active than ticarcillin against these organisms. Against 23 isolates of Proteus mirabilis, the activities of all of these drugs were similar. Although only a few isolates were available for testing, N-formimidoyl thienamycin displayed greater activity than either ticarcillin or tobramycin against indole-positive Proteus species.
More than 85% of the 16 Klebsiella pneumoniae isolates were inhibited by -0.25 jig of Nformimidoyl thienamycin per ml, whereas a concentration of 1 ,ug of tobramycin per ml was required to inhibit the same percentage of these isolates. Both drugs were substantially more active than ticarcillin. Similar differences in activ- There were only minor variations in the miniimal inhibitory concentrations of these same antibiotics among the different species. All organisms were inhibited by c2 ,ug of N-formimidoyl thienamycin per ml. The cumulative distribution curves are shown in Fig. 4 .
A total of 14 additional gram-negative bacillary isolates were tested, including Citrobacter spp. (five isolates), Klebsiella oxytoca (two isolates), Acinetobacter calcoaceticus subsp. anitratus (two isolates), Providencia stuartii (two isolates), Shigella sonnei (one isolate), Aeromonas hydrophila (one isolate), and Salmonella sp. (one isolate). All were inhibited by c2 ,ug of N-formimidoyl thienamycin per ml. Ticarcillin and tobramycin inhibited 20 and 85%, respec- tively, of these organisms at the same concentration.
More than one-half of the 285 isolates tested were inhibited by 0.125 ,Ag of N-formimidoyl thienamycin per ml, the lowest concentration used for our in vitro tests, and 98% were inhibited by c2 ,ug/ml. All of the isolates tested, with the exception of one S. epidermidis isolate, were inhibited by '8 ,ug of N-formimidoyl thienamycin per ml; this single S. epidermidis isolate was not inhibited by 32 ,tg/ml. DISCUSSION This study demonstrates that N-formimidoyl thienamycin is a highly active antimicrobial agent which is capable of inhibiting in vitro a variety of aerobic and facultatively anaerobic bacteria. This drug is a crystalline derivative of thienamycin, a bactericidal cell wall-active antibiotic (5 231, 1979) .
Because of its remarkable activity against many clinically encountered human bacterial pathogens, this agent appears to be especially promising. Further studies of its pharmacokinetics, in vivo activity, and toxicity will be of interest.
